メニューにジャンプコンテンツにジャンプ

トップページ > Surveillance of antifungal use, based on data from the NDB

Surveillance of antifungal use, based on data from the NDB

Surveillance of antifungal use, based on data from the NDB (published on July 13, 2020)

Data from 2013 to 2017 are available.

Figures PDF

Tables Excel

The data were surveyed in accordance with the study below.
Research grant from the Ministry of Health, Labour and Welfare of Japan (H29-shinkougyousei-shitei-005).
Research on the implementation of the AMR Action Plan (Chief: Norio Ohmagari)

Notes

  • The data are calculated from claims registered in the NDB. The data do not always reflect the precise antibiotic use because the data of patients who receive publicly funded health care are not always included. The numerical values are different from those of the surveillance of antibiotic sales (http://amrcrc.ncgm.go.jp/surveillance/020/20190902163931.html) due to the different data source.
  • The figures indicate drug utilization standardized by defined daily dose (DDD) per population and drug, called DID (DDDs/1,000 inhabitants/day) (Reference: https://www.whocc.no/atc_ddd_index/). The DDD is according to data published on January 1, 2017.
  • Please see this PDF (http://amr.ncgm.go.jp/pdf/190903_glossary.pdf) for definitions of terminology related to the surveillance of antibiotics.